当前位置: X-MOL 学术Bioconjugate Chem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Perspectives on the Future of Nanomedicine to Impact Patients: An Analysis of US Federal Funding and Interventional Clinical Trials.
Bioconjugate Chemistry ( IF 4.0 ) Pub Date : 2020-01-10 , DOI: 10.1021/acs.bioconjchem.9b00818
Anthony J McGoron 1
Affiliation  

The US and governments around the world, and companies, have made a considerable investment in nanomedicine, and there have been important discoveries. Nevertheless, there has been considerable debate as to whether the investment, both in money and in time, has been worth it. That question is not yet definitively answerable. However, investigators (and investors) might also wonder if the efforts in nanomedicine are likely to continue at the same pace as over the past decade. For this paper, an analysis was done by searching Medline, RePORT, the DOD (CDMRP), the NSF, and ClinicalTrials.gov. The major findings from the analysis are as follows: (1) The number of journal articles on the subject of nanomedicine continues to steadily rise and the areas "Drug Carriers" and "Drug Delivery Systems" are experiencing particularly rapid growth. (2) The level of funding from the Department of Health and Human Services (NIH and others) for indications other than cancer has been greater than that for cancer. (3) Funding for applications in HIV/AIDS has been strong. (4) Most of the cancers are being impacted. (5) The number of clinical trials are more highly focused in breast, skin, metastatic, and ovarian cancers, though the noncancer indications of pain and infections are also highly represented. The trials are primarily in Phases I and II, suggesting a long horizon before translating to a high impact on patients. (6) The vast majority of the clinical trials are for the evaluation of established nanomedicine formulations (liposomes and nab-paclitaxel/Abraxane) in combination with other therapies. Nevertheless, the number of clinical trials with other nanomedicine formulations has been increasing since 2009. Relatively few of the trials are for micelles or dendrimers. Taken as a whole, the analysis provides a picture that nanomedicine continues to be highly funded and highly studied but with few recent breakthroughs. Nanomedicine has yet to provide the "silver bullet" for therapy in cancer or other diseases, and it remains unclear whether it ever will.

中文翻译:

纳米药物影响患者的未来展望:美国联邦资助和介入性临床试验分析。

美国和世界各国政府以及公司已经在纳米医学上进行了大量投资,并且已经有了重要发现。然而,关于金钱和时间上的投资是否值得,存在着大量的争论。这个问题尚未完全解决。但是,研究人员(和投资者)也可能想知道,纳米医学的努力是否会继续以过去十年的速度发展。对于本文,通过搜索Medline,REPORT,DOD(CDMRP),NSF和ClinicalTrials.gov进行了分析。分析的主要发现如下:(1)关于纳米医学的期刊文章数量持续稳定增长,“药物载体”和“药物输送系统”领域 正在经历特别快速的增长。(2)卫生和公共服务部(NIH等机构)对癌症以外的适应症的资助水平高于癌症。(3)用于艾滋病毒/艾滋病的资金雄厚。(4)大多数癌症都受到影响。(5)尽管疼痛和感染的非癌适应症也很明显,但临床试验的重点更多地集中在乳腺癌,皮肤癌,转移性癌和卵巢癌。该试验主要在第一阶段和第二阶段进行,表明在转化为对患者的巨大影响之前需要较长的时间。(6)绝大多数临床试验是用于评估已建立的纳米药物制剂(脂质体和纳布紫杉醇/阿布沙烷)与其他疗法的组合。不过,自2009年以来,使用其他纳米药物制剂的临床试验数量一直在增加。相对而言,很少有针对胶束或树枝状聚合物的试验。从总体上看,该分析提供了一张图片,表明纳米医学继续得到高额资助和深入研究,但近期没有什么突破。纳米医学尚未为癌症或其他疾病的治疗提供“银弹”,目前尚不清楚是否会。
更新日期:2020-01-24
down
wechat
bug